Quantum BioPharma

Clinical-stage biotech targeting Multiple Sclerosis & Alcohol Health. Creators of unbuzzd™️ & Lucid-MS™️. Diversified Treasury. NASDAQ: $QNTM

[Quantum BioPharma @QuantumBP]

Quantum BioPharma continues advancing its Lucid-MS program with a focus on demyelination and neuroprotective pathways in Multiple Sclerosis.

Phase 1 complete. IND submitted for Phase 2 trial design.

Lucid-MS is investigational and not approved by FDA or Health Canada.

Sign up for email alerts : https://t.co/ttAoE2jw40

#Biotech #MultipleSclerosis #Demyelination $QNTM

[Quantum BioPharma @QuantumBP]

@SmellsDonkey @AnthonyDurkacz @zsaeed Hey there ! Dr. Lakshmi Kotra Is still a Senior Advisor at Quantum Biopharma. https://t.co/2guBJbnaiw

[Quantum BioPharma @QuantumBP]

Quantum BioPharma $QNTM is featured on The BioMedWire Podcast.

Anthony Durkacz (@AnthonyDurkacz ) discusses Lucid-MS, multiple sclerosis research, unbuzzd™, and key 2026 milestones.

Watch the full episode:
https://t.co/CQ4n735euF

#QNTM #QuantumBioPharma #LucidMS #BiotechStocks #MultipleSclerosis

[Quantum BioPharma @QuantumBP]

$QNTM

[AGORACOM - George @AGORACOM]

A 180-page commercialization study by Eversana projects $160 million in conservative first-year sales for Lucid-MS.

The report surveyed patients, doctors, key opinion leaders, and insurers across North America, Europe, and Japan.

Issued on behalf of @QuantumBP $QNTM

- MS market projected to exceed $30 billion by 2030

- Eversana validated demand from patients, physicians and insurers globally

Watch the full interview on AGORACOM Hub.

[Quantum BioPharma @QuantumBP]

#MSwalk #MSawareness

[MS Canada @MSCanOfficial]

On May 31, at #MSWalk, we’ll come together to show what happens when people show up for one another and for the future we all want to see, and we want you to join us.

Walk for your loved ones. Walk for your community. Walk for the cause. Register today: https://t.co/Y9JRfm3UIM

[Quantum BioPharma @QuantumBP]

#MSwalk #MSawareness

[680 CJOB @680CJOB]

What an incredible day at the Winnipeg MS Walk! Thousands of Canadians live with multiple sclerosis, and today the community came together to show support, raise awareness, and help fund vital research and programs. #MSWalk #Winnipeg

[Quantum BioPharma @QuantumBP]

#MSwalk #MSawareness

[89X Radio @89XRadio]

A big shout out to everyone who participated and supported this years #MSWalk!!

Every step fuels awareness, support, and research for those affected by MS!

@MSCanOfficial

[Quantum BioPharma @QuantumBP]

$QNTM

[AGORACOM - George @AGORACOM]

Quantum BioPharma submitted its Phase 2 IND to the FDA on March 30. Management said FDA clearance could come within 45 to 60 days.

Issued on behalf of @QuantumBP $QNTM

The 90-day toxicology study is now complete and submitted. Remaining FDA questions relate to interactions with existing MS therapies.

- FDA has a 30-day window to respond; management expects a letter imminently

- Internal team and CRO estimate 10 to 15 days to address any deficiencies

- If FDA raises no further concerns after responses are submitted, clearance follows

Watch the full interview on AGORACOM Hub.

[Quantum BioPharma @QuantumBP]

Most approved MS therapies are designed to modulate or suppress the immune system.

But the immune system may not be the whole story.

For decades, MS treatment has largely focused on reducing immune-driven attacks. Quantum BioPharma $QNTM is exploring a different scientific question: whether MS also involves neurodegenerative mechanisms tied directly to myelin damage.

This is the demyelination pathway.

Lucid-MS, also known as LUCID-21-302, is being developed as a non-immunomodulatory investigational new chemical entity designed to target PAD2 an enzyme involved in abnormal myelin protein citrullination, a process believed to increase myelin vulnerability in MS.

In preclinical animal models, Lucid-MS demonstrated signals supporting further research into this mechanism.

Rather than targeting the immune system, Lucid-MS is focused on the biology of demyelination itself.

A different mechanism. A different pathway. A different approach to MS research. No Drugs currently on the market that are approved do what Lucid-MS is designed to do.

Lucid-MS is a Investigational drug candidate. Not approved by the FDA or Health Canada. Currently in clinical development.

#Multiplesclerosis

[Quantum BioPharma @QuantumBP]

#MSWalkday #Multiplesclerosis

[MS Canada @MSCanOfficial]

MS Walk Day is here! 🎉

Across the country, thousands of people are coming together to raise awareness for Canadians living with #MS and their families.

Every participant, volunteer, and supporter brings us closer to a world free of MS ❤️.

#MSWalk #MultipleSclerosis

[Quantum BioPharma @QuantumBP]

Quantum BioPharma recently announced a key midpoint milestone in its separate collaborative imaging study with Massachusetts General Hospital, centered on [¹⁸F]3F4AP PET imaging to help assess demyelination in Multiple Sclerosis.

While this study is separate from Lucid-MS trials, we believe this type of imaging research could one day help support the broader scientific understanding of how demyelination is measured and tracked in MS research.

Lucid-MS has completed prior Phase 1 clinical development, and Quantum BioPharma has submitted an IND application to the FDA for a Phase 2 clinical trial.

As Quantum BioPharma’s lead investigational candidate, Lucid-MS was designed to target neurodegenerative pathways linked to the citrullination cascade, representing a differentiated scientific approach from traditional immunomodulatory therapies.

Learn more in our May 18, 2026 news release.
https://t.co/iZ1c9GlVlY

$QNTM #Biotech #NASDAQ #Multiplesclerosis

[Quantum BioPharma @QuantumBP]

Quantum BioPharma is proud to support #MSWalk and help raise awareness for those living with Multiple Sclerosis.

#MultipleSclerosis #MSAwareness #MSCommunity #MSResearch #Biotech

[MS Canada @MSCanOfficial]

“My favourite part of MS Walk is being surrounded by others who understand what it’s like to live with MS, that sense of connection is everything.” – Tina, diagnosed in 2019

Join #MSWalk on May 31 and help make sure no one faces MS alone: https://t.co/lWCTEtVSHW

[Quantum BioPharma @QuantumBP]

Quantum BioPharma CEO Interview with Zeeshan Saeed & Co Chair Anthony Durkacz | May 25, 2026
https://t.co/cPZxIPOSKV

#Biotech #Nasdaq #Multiplesclerosis #Neurodegenerative #Disease #Brainhealth #Interview #CEO $QNTM

[Quantum BioPharma @QuantumBP]

Most current MS therapies primarily focus on immune modulation.

Quantum BioPharma’s Lucid-21-302 is being developed to target a different mechanism involving citrullination-driven neurodegenerative processes associated with Multiple Sclerosis.

Track Quantum BioPharma’s progress as we advance our pipeline through clinical development.

Subscribe for official company announcements, regulatory filings, and investor updates:
https://t.co/ttAoE2jw40

$QNTM #Biotech #Nasdaq #Multiplesclerosis

[Quantum BioPharma @QuantumBP]

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

Promising Early Data Strengthens Potential of Novel PET Technology to Advance Development of Lucid-MS for Multiple Sclerosis

https://t.co/iZ1c9GlVlY

#MGH #Harvard #Biotech #MS #MultipleSclerosis #PETStudy #PETtracer #Demyelination #LucidMS $QNTM

[Quantum BioPharma @QuantumBP]

Quantum BioPharma recognizes that Multiple Sclerosis involves more than inflammation alone.

Scientific research has explored whether citrullination of Myelin Basic Protein (MBP) may alter myelin structure, contribute to demyelination, impair neural signaling, and play a role in neurodegenerative progression.

A different mechanism. A differentiated approach.
The unmet need in addressing the neurodegenerative component of MS remains significant.

Please visit https://t.co/n4XKHYbVA7 for more info.

#LucidMS #MultipleSclerosis #MSResearch #Neurodegeneration #Demyelination #Biotech #Pharma #Neuroscience $QNTM

[Quantum BioPharma @QuantumBP]

$QNTM #Multiplesclerosis #NASDAQ #Biotechnology

[AGORACOM - George @AGORACOM]

Multiple sclerosis involves damage to myelin — the protective layer surrounding nerve fibers.

Lucid-MS is being developed to target mechanisms associated with demyelination in MS.

Issued on behalf of @QuantumBP $QNTM

• Phase 1 safety and tolerability evaluation completed
• IND submitted as part of the regulatory process toward a planned Phase 2 program

What would you want to see demonstrated in future clinical development?